Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. Available in 2mg and 4mg strengths, the once-weekly subcutaneous injection demonstrated non-inferior efficacy and a comparable safety profile in Phase III studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eMFf0PI
via IFTTT

Read More

Natco, Eris Life to launch slimming shots in both Vial and Pen formats

Natco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pen formats. This move aims to make the treatment more affordable. Vials will be available first, targeting a wider patient base. Pens are expected later for metropolitan markets. This strategy offers patients pricing flexibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wPXzTLW
via IFTTT

Read More

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires

Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical companies are also preparing to launch their generic versions. This development promises significant cost savings for consumers seeking this medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSxs32K
via IFTTT

Read More

Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices

Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InWTzCi
via IFTTT

Read More

Small pharma companies seek price caps on inputs as costs surge

Indian pharmaceutical units face a severe crisis. Input costs have surged by 200-300 percent. This is due to global conflicts disrupting raw material supply. The Himachal Drug Manufacturers Association seeks government intervention. They want emergency price controls and a crisis task force. This aims to protect the industry and ensure medicine availability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nXC5bIZ
via IFTTT

Read More

Bharat Biotech bets on vaccines to fight drug resistance, eyes post-Covid growth

Hyderabad-based Bharat Biotech is developing novel vaccines to combat antimicrobial resistance (AMR), a significant global health threat. The company aims to administer these vaccines pre-surgery to prevent hospital-acquired infections, addressing a growing need due to rising drug resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ulNcXrk
via IFTTT

Read More

Pharma companies struggle as input costs rise despite 0.6% price hike

Facing a modest 0.6% hike in medicine prices this year, pharmaceutical companies are grappling with the rising costs of raw materials fueled by global unrest. Starting April 1, essential medications such as pain relievers and antibiotics will adjust in price, prompting the industry to appeal to governments for financial relief to manage these escalating expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RjCi2NE
via IFTTT

Read More

Chirag Paswan says India working with global bodies on nutraceutical regulations

India is actively working with international regulatory bodies, including Codex Alimentarius Commission, to develop essential regulations for the rapidly expanding nutraceutical sector. The government recognizes the immense growth potential and is committed to addressing existing gaps. This initiative aims to foster a structured environment for the industry's advancement, ensuring nutritional security alongside food security for the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LTHxBrU
via IFTTT

Read More

Zydus’s weight-loss injection to reach India via Lupin partnership

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/duKU36L
via IFTTT

Read More

Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in India

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and aids in chronic weight management. This collaboration aims to provide advanced therapies for metabolic disorders across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KkhBqjl
via IFTTT

Read More

SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement

In a surprising turn of events, the Supreme Court has scrutinised Sebi's ongoing actions against the directors of Sterling Biotech. This review arises following the directors’ hefty ₹5,100 crore settlement payment. Earlier, the court had invalidated all related cases. Sebi's investigation concerns the suspected routing of funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGoaAPK
via IFTTT

Read More

Sun Pharma’s Ilumya expansion bid gets USFDA nod for review

Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ZMkVv2
via IFTTT

Read More

India pharma production hit by propane shortage; vitamin, hormone supply at risk

India’s pharmaceutical industry is facing the risk of medicine shortages as a propane gas crunch forces several manufacturing units to partially or fully shut operations, disrupting production of key drugs including paracetamol, vitamins and hormones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zyTPBuk
via IFTTT

Read More

Mankind Pharma targets early Semaglutide launch

Mankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankind Pharma plans to offer the medication at affordable prices. This move aims to improve patient access to this important therapy. The company sees a significant opportunity as semaglutide's use extends beyond diabetes to other health areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tyGXjwh
via IFTTT

Read More

Plan afoot to merge 3 Delhi hospitals into single 'super medical hub'

In a revolutionary move for healthcare in Delhi, officials are consolidating Guru Teg Bahadur Hospital, the Delhi State Cancer Institute, and Rajiv Gandhi Super Speciality Hospital into a formidable medical hub. This initiative is not just about maximizing efficiency; it’s about reimagining patient care with cutting-edge resources and comprehensive services at their fingertips.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tQVsLDR
via IFTTT

Read More

Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

The rise of GLP-1 weight-loss drugs such as Ozempic is posing a challenge to the fitness industry, with cheaper generic versions expected to enter India soon. While some fear this could lead to a decline in gym memberships, others see it as an opportunity to offer specialised training and integrated wellness programmes to support people using these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C0UBNkr
via IFTTT

Read More

Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

A groundbreaking ceremony led by Union Minister Jitendra Singh has marked the start of a new Rs 600 crore pharmaceutical manufacturing plant in Kathua. This state-of-the-art facility will specialise in producing Amino Cephalosporanic Acid, a vital component of antibiotics. With this investment, India is set to bolster its pharmaceutical sector and lessen dependence on foreign imports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yeDE8hu
via IFTTT

Read More

West Asia war hits medical tourism: Overseas patient flow to Indian hospitals drops up to 75%

Israel-Iran war: Indian hospitals face a sharp decline in international patients. The ongoing conflict has disrupted travel, causing revenue losses. Hospitals report a 50% to 75% fall in overseas patient flows. This situation is prompting a shift towards attracting patients from Southeast Asia, Africa, and Central Asia. Recovery depends on regional stability and travel confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K07jhvu
via IFTTT

Read More

Ambuja Neotia Group to develop over Rs 700 cr integrated healthcare and hospitality project in Guwahati

Ambuja Neotia Group will build a large integrated healthcare and hospitality project in Guwahati. The Rs 700 crore investment will include a 300-bed multi-speciality hospital and a 4+ star hotel. This initiative aims to boost the region's healthcare infrastructure and economy. The project is expected to create thousands of jobs. It marks the group's second healthcare venture in Assam.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xielzBA
via IFTTT

Read More

'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

Bayer's CEO Bill Anderson believes India can become a top pharmaceutical market. He highlights the need for supportive policy frameworks, including stronger intellectual property protection. This will attract investment in cutting-edge drugs. India's young population and technological leadership offer significant opportunities. Bayer is investing in innovation centers in Bengaluru, leveraging Indian talent for global missions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kN8cZl1
via IFTTT

Read More

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT

Read More

India medical device shortage: Polypropylene price surge threatens syringes, IV bags amid Iran war

India's medical devices industry faces a polypropylene shortage due to the Iran war, causing a sharp price increase of over Rs 55 per kg. This surge, coupled with a deepening gas supply crisis impacting syringe production, threatens small and medium enterprises and overall healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPJiAtX
via IFTTT

Read More

Govt cautions pharma cos against surrogate ads for promoting GLP-1 drugs

Weight loss drug risks: The government has warned of strict regulatory action against those found using surrogate advertising to promote GLP-1 drugs. "A detailed advisory on the use of GLP-1 drugs is expected to be released in the next few days," sources told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9AnrLdw
via IFTTT

Read More

Decoding the antibiotic resistance crisis: How everyday habits can save our strongest medicines

Antibiotics are losing their power as germs grow stronger, a crisis fueled by everyday misuse. Experts urge parents to rethink treating minor ailments and fevers without medical advice. Preventing infections through simple hygiene practices like handwashing and sanitizing surfaces, summarized by the S.H.A.K.E. formula, is crucial to preserving these life-saving medicines for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3diYcxA
via IFTTT

Read More

Raw nerve: Drugs may get costlier as prices of ingredients surge 30%

India's medicine prices are poised for a sharp increase due to a 30% surge in raw material costs, driven by container ship scarcity following the Iran war. This scarcity is hindering the movement of crucial ingredients from China, impacting local manufacturing and potentially forcing producers to pass on higher expenses to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tk2Gyhv
via IFTTT

Read More

India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25

With API exports hitting an impressive Rs 41,500 crore last fiscal year, India has outperformed its imports of Rs 39,215 crore. The government is pushing for a self-reliant economy via the Production Linked Incentive scheme, strategically aimed at cutting down import connections, notably with China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qGlBJYv
via IFTTT

Read More

Pharma exporters seek freight sops and logistical support as costs rise

As tensions in West Asia escalate, Indian pharmaceutical exporters are grappling with surging costs. In response, Pharmexcil is advocating for government interventions, including freight subsidies and enhanced logistical support. Meanwhile, companies are pivoting towards alternative shipping routes and ramping up their buffer stocks in anticipation of potential disruptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HAW7DLB
via IFTTT

Read More

Looking beyond seasonal sniffles: Protecting children's immunity from climate instability

Climate change is disrupting traditional illness patterns, affecting children's health. Savlon Swasth India Mission promotes proactive hygiene with the S.H.A.K.E. formula. This strategy encourages sanitizing, handwashing, doctor consultations, wound care, and nutritious meals. These habits build resilience against unexpected illnesses. The mission has positively impacted millions of children through hygiene education programs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EbVX8jG
via IFTTT

Read More

Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDA

Cipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue, the US Food and Drug Administration has said. The recall affects specific batches distributed in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zEldipu
via IFTTT

Read More

HLL Lifecare to expand AMRIT Pharmacies to 550 outlets by 2027

HLL Lifecare will significantly expand its AMRIT pharmacy network across India. The number of outlets will more than double to over 550 by December 2027. This initiative aims to make life-saving medicines and implants more affordable and accessible. Special focus will be on underserved and remote regions. The expansion involves an investment of Rs 100 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5SmdnUW
via IFTTT

Read More

India set to lead global homoeopathy with certified quality frameworks: Experts

India is set to lead the global homoeopathy market. Strong clinical expertise and practitioner networks are driving this growth. Internationally recognised quality certifications like AYUSH Premium Mark and NABL accreditation are key. Indian brands are now well-positioned to challenge established European dominance. This marks a significant shift in the global homoeopathy landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pObwAGH
via IFTTT

Read More

Middle East conflict hits medical tourism, Indian hospitals tap other markets

Indian hospitals are diversifying patient sources to Southeast Asia, Africa, and Central Asia as the Middle East conflict disrupts medical travel. This shift aims to mitigate revenue losses from the region, which contributes significantly to their medical value travel earnings. Hospitals are also enhancing teleconsultation services and seeking government support for direct flights to maintain patient inflows.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7cAkRfo
via IFTTT

Read More

Cipla recalls over 400 cartons of cancer drug in US: FDA

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary Class III recall, meaning it is not expected to cause adverse health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tdnVDy3
via IFTTT

Read More

FDA official overseeing vaccines resigns amidst controversy

A key US Food and Drug Administration official responsible for vaccines is departing at the end of April. Vinay Prasad faced criticism for health policy decisions, particularly concerning Covid-19 vaccine efficacy. His exit follows controversies, including refusing to review a flu vaccine application. Prasad had previously raised doubts about Covid-19 vaccine safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WejPXN
via IFTTT

Read More

Key drug prices may surge on hoarding and higher demand

Escalating Middle East conflict is expected to increase demand for essential medicines. This surge could lead to higher drug prices, potentially benefiting Indian pharmaceutical manufacturers. Companies are monitoring the situation closely. Increased demand for chronic and acute therapy drugs is anticipated. Indian firms may see export disruptions but also higher overall demand if the conflict extends.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S615dwf
via IFTTT

Read More

Obesity & diabetes are world's next health "tsunami", warns ebola discoverer Peter Piot

A leading virologist warns of a global tsunami of obesity and diabetes, surpassing viral threats. India faces significant vulnerability as diabetes rates surge. While pandemic preparedness has improved technically, societal trust remains a challenge. Innovations like new anti-obesity drugs offer hope but require broader access and lifestyle changes. India should prioritize discovery and innovation in biopharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kTQ8t5R
via IFTTT

Read More

Pharma exports may take up to $500 million hit as freight costs rise

India's drug exports face a significant threat from the Iran war. Higher freight costs and shipping companies avoiding Gulf routes could impact shipments worth $300-500 million. This disruption affects both raw material imports from China and finished product exports to West Asia and beyond. Companies are building inventories to manage potential delays.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ibVD5SK
via IFTTT

Read More

India & China must-win markets on rising middle-class households: Reckitt Chief

Reckitt Benckiser sees India and China as vital growth markets. The company's CEO highlighted the expanding middle class in these nations. Emerging markets are driving Reckitt's revenue expansion. India and China showed strong growth in the last quarter. This performance helped offset weaker results in developed markets. Reckitt aims to increase its reach in India through improved distribution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90FKEjL
via IFTTT

Read More

Iran war could disrupt India’s pharma exports by up to $500 million

The Iran war is impacting India's drug exports. Higher freight costs and shipping refusals to Gulf hubs are causing concern. Industry estimates suggest a potential loss of $300-$500 million. While manufacturing remains unaffected, logistics are complicated. Companies are maintaining inventories to ensure supply continuity. The situation could lead to temporary supply challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j9pxiSV
via IFTTT

Read More

India pharma exports risk disruption if Middle East conflict widens

Indian drug exports face significant challenges. A wider Middle East conflict could disrupt vital shipping routes. This may lead to longer transit times for temperature-sensitive medicines. Increased freight costs and potential delays in key markets like the UAE and Saudi Arabia are also concerns. Air cargo routes are also at risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhIpoxs
via IFTTT

Read More

Urban India faces metabolic health crisis as 73 million are overweight or obese

In India's vibrant urban landscape, obesity and diabetes are becoming formidable adversaries. A new analysis highlights that while countless individuals are caught in the grip of these health challenges, there's a startling lack of awareness about innovative GLP-1 weight loss medications. Interestingly, informed individuals express considerable eagerness to explore these options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35PxcKE
via IFTTT

Read More

Ahead of its time, a GLP-1 drug almost made it out of India

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes management and weight loss. Unfortunately, due to prohibitive clinical trial costs and a skeptical outlook on the obesity market, Zydus chose to shelve further development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bFBIjhY
via IFTTT

Read More

Child hears again 18 months after brain stem implant at AIIMS

A young boy in India has received a groundbreaking auditory brain stem implant. This marks a first for AIIMS. The surgery was performed after conventional implants were not suitable. The child is now responding to sounds and speaking more clearly. Doctors highlight the importance of early detection for hearing loss.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DiS2nva
via IFTTT

Read More

NATCO Pharma launches generic blood cancer treatment medicine in US

NATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version of Celgene's Pomalyst. The launch is in partnership with Breckenridge Pharmaceutical. This move aims to make specialty medicines accessible. It offers an affordable solution for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/845bQ6z
via IFTTT

Read More

Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave

Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET that the company sees room for both branded innovator drugs and generics to thrive simultaneously in the rapidly expanding domestic segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ks8Hj03
via IFTTT

Read More

All our AI models have scientists in loop, says MSD chief AI officer

MSD's Chief AI Officer, Anton Groom, highlights AI's transformative role in drug discovery. AI models like TEDDY and KERMT are assisting scientists, identifying new drug targets and refining lead identification. This technology is accelerating the development of new medicines, with two AI-discovered molecules already in clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/utByhpW
via IFTTT

Read More

Brain can keep producing new neurons in old age, but Alzheimer’s may disrupt the process: Study

New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer's patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CarbWi1
via IFTTT

Read More